AAPG
Ascentage Pharma Group InternationalNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.62B
P/E Ratio
—
EPS
$-2.02
Beta
0.81
52W High
$48.45
52W Low
$17.55
50-Day MA
$23.99
200-Day MA
$32.86
Dividend Yield
—
Profit Margin
-216.50%
Forward P/E
—
PEG Ratio
—
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Fundamentals
| Revenue (TTM) | $574.12M |
| Gross Profit (TTM) | $525.18M |
| EBITDA | $-1.13B |
| Operating Margin | -193.30% |
| Return on Equity | -154.60% |
| Return on Assets | -23.00% |
| Revenue/Share (TTM) | $6.45 |
| Book Value | $0.52 |
| Price-to-Book | 13.27 |
| Price-to-Sales (TTM) | 4.57 |
| EV/Revenue | 28.92 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 117.00% |
| Shares Outstanding | $93.33M |
| Float | $283.99M |
| % Insiders | 0.00% |
| % Institutions | 0.08% |
Analyst Ratings
Consensus ($49.14 target)
2
Strong Buy4
BuyData last updated: 4/7/2026